ClinicalTrials.gg
RecruitingNCT07423169Updated Feb 20, 2026

Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer

An interventional study of Partial Tumor Irradiation in Lung Adenocarcinoma, Bulky Tumors and Unresectable Cancer, sponsored by Karl Landsteiner University of Health Sciences. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Karl Landsteiner University of Health Sciences · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The present study will explore a novel treatment strategy for unresectable lung adenocarcinoma combining a unique unconventional radiotherapy technique for high dose partial tumor irradiation (PTI) sparing the peritumoral immune microenvironment (PIM) with an immune checkpoint inhibitor (ICI)-based immunotherapy. The present study will focus on patients with larger, unresectable bulky lung tumors who previously failed standard of care therapy, or are unsuitable for conventional radio-chemotherapy due to tumor size and volume, and do not have any further therapeutic option left. This concept implies that a very high, ablative radiation dose (typically 20-25Gy per fraction) is delivered exclusively to the central bulky-tumor segment sparing at the same time surrounding PIM and therefore preserving its function.

The present study will explore the potential clinical advantages of the above described innovative treatment concept as a rechallenge treatment: following the disease progression during initiated first-line ICI-therapy, or following discontinuation of ICI-therapy, a same previously used agent (ICI) will be added the PTI to boost its immunologic anti-tumor effects. The treatment response will be measured by comparing the progression-free survival 1 (PFS-1) (ICI-therapy alone) and progression-free survival 2 (PFS-2) (combined rechallange PTI-ICI) rates.

The primary endpoint will be ∆PFS rate (PFS-2 vs PFS-1) assessed according to the modified iRECIST criteria. Secondary endpoints will include overall survival, toxicity, and exploration and validation of the anti-cancer immunity.

Once treatment is completed, follow up will be performed on a regular basis (at 6 and 12 weeks, and every 3 months later on) by CT, MRT or PET-CT imaging to allow for endpoints assessment, or at any time in case of suspected disease progression. Patients will also be followed clinically with history and physical examinations, vital signs, and laboratory examinations as indicated.

Read the detailed description

The present study will explore a novel treatment strategy for unresectable lung adenocarcinoma combining a unique unconventional radiotherapy technique for high dose partial tumor irradiation (PTI) sparing the peritumoral immune microenvironment (PIM) with an immune checkpoint inhibitor (ICI)-based immunotherapy. The present study will focus on patients with larger, unresectable bulky lung tumors who previously failed standard of care therapy, or are unsuitable for conventional radio-chemotherapy due to tumor size and volume, and do not have any further therapeutic option left. The present novel, combined approach will be offered as an alternative to a palliative or best supportive care. In previous studies PTI has shown to be effective, safe and capable of inducing significant immunomodulatory and neoadjuvant effects in complex unresectable resistant bulky tumors, lung cancer including. PTI was previously explored alone, therefore so far never combined with any kind of systemic therapy, in order first to assess its own efficiency when immunomodulation and tumor control is concerned. Its combination with immunotherapy is very attractive due to its high immunostimulative potential as shown in previous studies. Aditionally, it has been shown that the PD-L1 level is widely upregulated after radiotherapy, on not only tumor cells, but also macrophages, myeloid-derived suppressor cells, and derived exosomes, which correlate to improved effectiveness of immunotherapy resulting in better therapeutic outcomes. Taking all together into account, it is expected from the PTI-ICI combination to generate more powerful immunomodulatory anti-tumor effect compared to the conventional radiotherapy combination with immunotherapy leading to improved tumor control and prognosis. One of the reasons for this is the PTI´s sparring effect of PIM, which otherwise is irradiated with a full dose of radiation when conventional radiotherapy is used and therefore destroyed, which is why the same conventional radiotherapy is quite immunosuppressive and is not expected to work optimally when combined with immunotherapy. In order to improve the radiotherapy therapeutic ratio by the highly complex unresectable tumors left without other therapeutic options, PTI was purposefully designed to add to the radiation-mediated tumor cell killing component, an additional component of radiation-induced immune-mediated tumor cell killing, a concept known as the "radiation-vaccine". This concept implies that a very high, ablative radiation dose (typically 20-25Gy per fraction) is delivered exclusively to the central bulky-tumor segment sparing at the same time surrounding PIM and therefore preserving its function. PTI is going to be delivered as a single fraction (1 day) in order to release the tumor antigens and pro-inflammatory cytokines from destroyed tumor cells which could then sensitize loco-regional (previously spared) immune cells surrounding the tumor, resulting in an immune anti-tumor response, like a true vaccine.

For the purpose of PTI-treatment planning, the targeted central tumor segment, or so-called BTV (Bystander Tumor Volume), will be delineated using the combination of 18F-FDG-PET-CT (PET-CT; not mandatory, if performed by patient for the purpose of the staging) and contrast-enhanced CT (mandatory). In case there is no PET-CT available at time of treatment planning the BTV will simply be contoured as the Gross Tumor Volume (GTV) minus 5-10mm. This margin will depend on the proximity of the nearby organs at risk (OAR) (excluding main bronchus or heart). PTI will be delivered with photons by means of stereotactic body radiotherapy (SBRT) technique. Based on tumor location, its volume and risk factors related to nearby critical structures, radiation dose might be reduced to 15Gy/fraction, according to patient´s individual risk factors, respectively. Regarding the ICI, an anti-PD-L1 antibody will be administered at three-week intervals until progression.

The present study will explore the potential clinical advantages of the above described innovative treatment concept as a rechallenge treatment: following the disease progression during initiated first-line ICI-therapy, or following discontinuation of ICI-therapy, a same previously used agent (ICI) will be added the PTI to boost its immunologic anti-tumor effects. The treatment response will be measured by comparing the progression-free survival 1 (PFS-1) (ICI-therapy alone) and progression-free survival 2 (PFS-2) (combined rechallange PTI-ICI) rates.

The analysis of the bio-molecular mechanisms potentially responsible for the observed clinical effects of the PTI-ICI treatment in terms of radiation-induced anti-tumor immune response will also be performed. This will include the anti-tumor immunity as profiling of peripheral blood mononuclear cells (PBMC) following the PTI-ICI therapy through translational immune studies on blood specimens. Two key cytokines that are involved in modulation of immune response, Interleukin-2 (IL-2) and Interferon Gamma (INFg), will serially be assessed, at baseline, after radiotherapy treatment, before each administration of the ICI in order to determine their potential role in immunomodulation by PTI-ICI.

This is a pilot study in which the investigators will enroll up to 10 patients with locally advanced or metastatic unresectable lung adenocarcinoma to assess the feasibility and potential effectiveness of a novel approach.

The hypothesis implies that for an effective immune modulation leading to improved therapeutic ratio, the entire tumor volume may not need to be irradiated but only a partial tumor volume sparing the PIM, in order to overcome the tumor tolerance initiating the immune cycle in radiation-spared PIM, resulting in tumoricidal radio-immune anti-tumor effects.

The primary endpoint will be ∆PFS rate (PFS-2 vs PFS-1) assessed according to the modified iRECIST criteria. Secondary endpoints will include overall survival, toxicity, and exploration and validation of the anti-cancer immunity.

Once treatment is completed, follow up will be performed on a regular basis (at 6 and 12 weeks, and every 3 months later on) by CT, MRT or PET-CT imaging to allow for endpoints assessment, or at any time in case of suspected disease progression. Patients will also be followed clinically with history and physical examinations, vital signs, and laboratory examinations as indicated.

02

Conditions studied

  • Lung Adenocarcinoma
  • Bulky Tumors
  • Unresectable Cancer

Keywords

  • Partial Irradiation
  • Immunomodulation
  • Radio-Vaccine
03

In context

Adenocarcinoma of Lung

418 studies on the registry are indexed under Adenocarcinoma of Lung; 78 are open to participants now.

This study's planned enrollment of 10 is below the median of 60 across 293 interventional studies indexed under Adenocarcinoma of Lung.

Browse Adenocarcinoma of Lung studies →

Lead sponsor

Karl Landsteiner University of Health Sciences is the lead sponsor of 13 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written
  2. proven unresectable lung adenocarcinoma
  3. Ineligibility for surgery and conventional curative (whole tumor) radiotherapy, and to any previous standard of care therapy including ICI
  4. Age ≥ 18 years,
  5. Female patients must either be of non- (i.e. by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) OR women of fertile age must have adequate conception prevention measures and must have a negative serum pregnancy test upon study entry,
  6. Patient is willing and able to comply with the follow up including scheduled visits and examinations,
  7. Adequate immune blood profile (not being immunodepressed): Leucocyte count ≥4000, Neutrophils count ≥1000.
  8. PDL-1 ≥ 1%

Exclusion criteria

Exclusion Criteria:

  1. Patients with resectable/curable lung cancer
  2. Tumors suitable for the standard of care therapies including surgery or conventional curative (whole tumor) radio-chemotherapy
  3. Lung cancer histology other than adenocarcinoma
  4. Female patients who are pregnant, breast-feeding or male or female patients of who are not employing an effective method of
  5. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, (1)
  6. Patients with uncontrolled seizures.
  7. Inadequate immune blood profile (being potentially immunodepressed): Leucocyte count \<4000, Neutrophils count \<1000.
  8. PDL-1 \< 1%
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Unresectable, bulky lung adenocarcinoma

    The present study will explore a novel treatment strategy for unresectable lung adenocarcinoma combining a unique unconventional radiotherapy technique for high dose partial tumor irradiation (PTI) sparing the peritumoral immune microenvironment (PIM) with an immune checkpoint inhibitor (ICI)-based immunotherapy. The present study will focus on patients with larger, unresectable bulky lung tumors who previously failed standard of care therapy, or are unsuitable for conventional radio-chemotherapy due to tumor size and volume, and do not have any further therapeutic option left. The present novel, combined approach will be offered as an alternative to a palliative or best supportive care. This concept implies that a very high, ablative radiation dose (typically 20-25Gy per fraction) is delivered exclusively to the central bulky-tumor segment sparing at the same time surrounding PIM and therefore preserving its function. PTI is going to be delivered as a single fraction (1 day).

    Radiation: Partial Tumor Irradiation

Interventions

  • RadiationPartial Tumor Irradiation

    A very high, ablative radiation dose of 20-25Gy will be delivered exclusively to the central bulky-tumor segment sparing at the same time surrounding Peritumoral Immune Microenvironment and therefore preserving its function. Partial Tumor Irradiation is going to be delivered as a single fraction (1 day-treatment).

06

What researchers measure

Primary outcomes

  1. ∆Progression-Free Survival (PFS) rate (PFS-2 vs PFS-1)

    ∆Progression-Free Survival (PFS) rate measured as a time-difference (in months) between the survival free from tumor progression at local and distant site of initial ICI treatment (PFS-1) and rechallenge PTI-ICI (PFS-2).

    Time frame: From radiotherapy treatment to the end of follow up period at 12 months

Secondary outcomes

  1. Overall survival

    Calculated as the time (in months) from treatment initiation to death.

    Time frame: From radiotherapy treatment until the date of death from any cause assessed up to 12 months

  2. Toxicity: presence of any treatment-related adverse events/side effects

    Number of Participants With Treatment-Related Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0

    Time frame: From radiotherapy treatment initiation to the end of follow up period at 12 months

  3. Validation of the anti-cancer immunity by the absolute counts of peripheral blood mononuclear cells (PBMC)

    Measures the absolute counts of peripheral blood mononuclear cells (PBMC)

    Time frame: From radiotherapy treatment to the end of follow up period at 12 months

  4. Validation of the anti-cancer immunity by the absolute counts of surface marker expression

    Measures the absolute counts of surface marker expression (CD markers) of the CD4+ T Cells, CD8+ T Cells, CD19+ B Cells, CD14+ Monocytes

    Time frame: From radiotherapy treatment to the end of follow up period at 12 months

  5. Validation of the anti-cancer immunity by the concentration (pg/mL or IU/mL) of immunoregulatory cytokines

    Measures the concentration (pg/mL or IU/mL) of Interleukin-2 (IL-2) and Interferon-gamma (IFNg)

    Time frame: From radiotherapy treatment to the end of follow up period at 12 months

07

Study locations

1 of 1 sites recruiting
  • Radiation Oncology Department
    Krems, Austria 3500, Austria
    Recruiting
    • Slavisa Tubin, MD · Contactslavisa.tubin@krems.lknoe.at · +43 02732 90040
    • Slavisa Tubin, MD · Principal investigator
    • Peter Errhalt, Prim. Clin. Ass. Prof. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Demographics, Patient- and Tumor-features

Supporting information: Study protocol, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 20, 2026
StartActual
Feb 2, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07423169
Lead sponsor
Karl Landsteiner University of Health Sciences
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Feb 2, 2026
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Feb 20, 2026

Study contacts

Slavisa Tubin, MD
Contact
slavisa.tubin@krems.lknoe.at
+43 02732 90040
Slavisa Tubin, MD
principal investigator · University Clinic Krems, Radiation Oncology Department

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion